Evaluating national pricing policies of innovative anti-cancer drugs: correlation analysis between costs and survival in 15 European countries
Evaluating national pricing policies of innovative anti-cancer drugs: correlation analysis between costs and survival in 15 European countriesIntroductionIn recent years, public health systems in Europe have faced the challenge of sustainability in different ways. The aim of this study is to analyse...
Main Authors: | Daniele Mengato, Francesca Decannas |
---|---|
Format: | Article |
Language: | English |
Published: |
AboutScience Srl
2016-11-01
|
Series: | Global & Regional Health Technology Assessment |
Online Access: | http://www.grhta.com/Attach/1CC89769-BA86-49DC-91CA-459871BD5E2C/E4DB0A74-9FE6-4126-9F7A-57A583A4AD62 |
Similar Items
-
Pricing of innovative drugs: correlation between incremental cost and survival gain in four countries
by: Daniele Mengato, et al.
Published: (2016-07-01) -
by: Daniele Mengato, et al.
Published: (2019-11-01) -
The impact of pricing strategy on the costs of oral anti‐cancer drugs
by: Judy Truong, et al.
Published: (2019-07-01) -
Axicabtagene ciloleucel in non-Hodgkin lymphoma: the restricted mean survival time as a tool for estimating progression-free life expectancy better than the median
by: Andrea Messori, et al.
Published: (2020-06-01) -
A comparison of generic drug prices in seven European countries: a methodological analysis
by: Olivier J. Wouters, et al.
Published: (2017-03-01)